Month: November 2024

.China’s Duality Biotherapeutics has submitted (PDF) documents for a Hong Kong IPO, looking for a hidden sum to power a vast pipe of antibody-drug conjugates

.Though Alkeus Pharmaceuticals’ dental eye disease property neglected to dramatically minimize geographic atrophy (GA) lesion growth, the biotech is citing “scientifically purposeful” results and a

.While the biotech expenditure scene in Europe has actually reduced rather complying with a COVID-19 backing boom in 2021, a brand-new report from PitchBook suggests

.Merck &amp Co. has actually rapidly recouped a few of the expenses of its own Harp on Therapies acquistion, attracting $170 million in advance through

.Merck &amp Co. has actually rapidly recouped a few of the expenses of its own Harp on Therapies acquistion, attracting $170 million in advance through

.Cullinan Therapeutics was impressed enough with Port BioMed’s bispecific immune activator that it surrendered $25 thousand in 2013 for the medication’s U.S. liberties. However, having

.Welcome to recently’s Chutes &amp Ladders, our summary of significant leadership hirings, firings and retirings throughout the market. Feel free to send out the good

.Compass Pathways’ quest to phase 3 experimental anxiety data is actually taking longer than anticipated. Along with the trials swamping by months, the biotech is

.Tip has actually disclosed stage 3 data on its own near-approval discomfort medicine applicant suzetrigine, clarifying just how the non-opioid painkiller integrates with advil and

.Cognition Therapeutics’ period 2 SHINE trial has taken some of the appeal off the Alzheimer’s health condition medicine prospect CT1812. The oral sigma-2 villain neglected